Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 16/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15901472 | 1.00 | PLA2G7 (0.47) | PLA2G7PPARGHDAC1HDAC6HDAC5 | |
| SCHEMBL15901176 | 0.89 | PLA2G7 (0.47) | PLA2G7 | |
| SCHEMBL15901178 | 0.89 | PLA2G7 (0.47) | PLA2G7 | |
| SCHEMBL15902732 | 0.88 | PLA2G7 (0.42) | PLA2G7P2RX3 | |
| SCHEMBL15902731 | 0.88 | PLA2G7 (0.42) | PLA2G7P2RX3 | |
| SCHEMBL15900987 | 0.86 | PLA2G7 (0.48) | PLA2G7 | |
| SCHEMBL15900988 | 0.86 | PLA2G7 (0.48) | PLA2G7 | |
| SCHEMBL15900895 | 0.85 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15900892 | 0.85 | PLA2G7 (0.49) | PLA2G7 | |
| SCHEMBL15900977 | 0.84 | PLA2G7 (0.51) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948452-B1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-08-09 | — | — | EP | claimed |
| EP-2948452-B1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-08-09 | — | — | EP | disclosed |
| US-9708330-B2 | 2,3-dihydroimidazol[1,2-C]pyrimidin-5(1-H)-one based ipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-18 | — | — | US | disclosed |
| US-20150361082-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9051325-B2 | Bicyclic [5,6] imidazo pyrimodone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20140213599-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213599-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | PLA2G7 2/4885PPARG 576/4885HDAC1 1244/4885 |
| US-20150361082-A1 | 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1-H)-ONE BASED IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA2) INHIBITORS | PLA2G4A, PLA2G4C, PLA2G4B | PLA2G7 16/4885PPARG 796/4885HDAC1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.